

蘇冠賓

E-mail: cobolsu@gmail.com

目前職務

中國醫藥大學

- 醫學院 教授 (2012.11-) 兼副院長 (2017.8-)
- 身心介面 (Mind-Body Interface) 研究中心 主持人 (2006.8-)
- 附設醫院 精神醫學部一般精神科 主任 (2004.3-)
- 倫敦大學國王學院 訪問教授 (2008.11-)

個人專業經歷

中國醫藥大學

- 中國醫藥大學 神經科學及認知科學研究所所長 (2014.8-2017.8)
 - 附設醫院 精神科主任 (2002.3-2004.3)
- 台北醫學大學 (1999.5.-2002.3.) 講師、萬芳醫院主治醫師
台北市立療養院 住院醫師、總醫師、兼任主治醫師 (1995.7.-2002.3.)

教育程度

- 高雄醫學大學 醫學士 (1988-1995)
- 倫敦大學國王學院 精神醫學所 博士 (2005-2008)

榮譽與獲獎

- 2016。「國際脂肪酸研究學會早期研究生涯成就獎 Early Career Award」
- 2013。英國精神藥理學會 精神藥理研究獎
- 2013。葛蘭素史克憂鬱症與焦慮症研究論文獎，台灣精神醫學會
- 2013。「張文和教授研究論文獎」，台灣生物精神醫學會
- 2012 及 2014。「國際脂肪酸研究學會」年輕學者獎
- 2012。「泛太平洋精神醫學會」年輕學者獎
- 2012。美國精神醫學研究學會「年輕研究學者獎」
- 2012。中國醫藥大學深耕計畫補助
- 2012。中國醫藥大學附設醫院教學優良獎
- 2011。湯森路透科學卓越研究獎
- 2011。葛蘭素史克憂鬱症與焦慮症研究論文獎，台灣精神醫學會
- 2011。台灣與英國頂尖大學前期合作研究計畫，國科會
- 2011。中國醫藥大學附設醫院「醫師科學家」獎助
- 2010。吳大猷先生紀念獎，國科會
- 2010。中國醫藥大學附設醫院傑出醫師 (Elite Physician)
- 2009。中國醫藥大學研究績優及論文績優最佳獎
- 2009。中國醫藥大學附設醫院年度優良醫師
- 2008。第一屆「張文和教授研究論文獎」，台灣生物精神醫學會
- 2008-2010。「美國國家精神分裂症及憂鬱症研究聯盟 (NARSAD)」年輕學者獎
- 2008。英國精神藥理學會第一屆 Professor Robert Kerwin 論文獎
- 2008。商業週刊 (Business Weekly) 台灣「百大名醫」
- 2007-2008。中國醫藥大學「菁英教師國外研究」獎助

其他(委員會或
學會會員)

- 2006-2007。中國醫藥大學附設醫院「出國進修菁英計畫」獎助
- 2006及2007。「歐洲神經精神藥理學會」論文獎
- 2006及2007。論文報告獎助：倫敦大學國王學院；駐英國代表處
- 2006。保羅楊森博士「精神分裂病研究論文獎」，台灣精神醫學會
- 2005-2006。教育部公費留學生獎學金「專案培育計畫」，台灣教育部
- 2004。中國醫藥大學附設醫院年度優良醫師

- 2016年，國際脂肪酸研究學會 理事(2016-2020)
- 2016年，台灣營養精神醫學研究學會 Taiwan Society for Nutritional Psychiatry Research (TSNPR) 理事長
- 2015年，台灣生物精神醫學暨神經精神藥理學學會 第七屆理事
- 2015年，第六屆營養及生理活動國際研討會 International Conference on Nutrition and Physical Activity (NAPA 2015) 大會副主席
- 2015年，世界精神醫學會國際大會 World Psychiatry Association International Congress (WPAIC) Executive Committee 執行委員
- 2010~2016年，第一至六屆國際研討會 Mind-Body Interface International Symposium 大會主席
- 2014年起，期刊 Clinical Psychopharmacology Neuroscience 編輯委員
- 2013年起，國際營養及精神醫學研究學會 International Society for Nutritional Psychiatry Research (ISNPR) 理事
- 2013年起，期刊 J Traditional Complementary Medicine 編輯委員
- 2012年起，期刊 Psychiatry Investigation 編輯委員
- 2010年起，台灣自殺防治學會國際事務委員會委員
- 2009年起，台灣精神醫學雜誌執行編輯
- 2009年起，國際藥理經濟學會(ISPOR)亞洲分會臨床委員及編輯委員
- 2007年起，歐洲精神神經藥理學會(ECNP)會員
- 2007年起，英國神經藥理學會(BAP)會員
- 2007年，DEPRESSION: BRAIN CAUSES, BODY CONSEQUENCES, King's College London, UK (國際研討會籌備執行委員)
- 2006年起，Bipolar Disorders Update 期刊編輯委員
- 2005年起，國際性雙極型情感性疾患學會(ISBP)會員

研究計劃

計劃主持人：

- 科技部 2017-2020 年。慢性疼痛與憂鬱症共病的生物機制及臨床分型：探討中樞敏感化的分子機轉 (MOST106-2314-B-039-027-MY3)
- 國家衛生研究院整合性醫藥衛生科技研究計畫 (創新研究計畫) 2016-2018 三年。N-3 不飽和脂肪酸做為第一線憂鬱症治療與預防：從生物標誌到臨床分型之探討 (NHRI-EX105-10528NI)
- 科技部 2015-2017 年。探討憂鬱症之炎症假說：干擾素誘發憂鬱症之基因體學研究—二年計劃 (MOST104-2314-B-039-022-MY2)

- 科技部 2014-2017 年。N-3 多元不飽和脂肪酸對於憂鬱症療效之藥物基因體學研究－三年計劃 (MOST103-2320-B-039-039-MY3)
- 中國醫藥大學附設醫院 2015-2016 年。發炎、疼痛與憂鬱症的分型，憂鬱症患者潛在疼痛症狀的機制 (CMU104-S-16-03)
- 中國醫藥大學附設醫院 2015-2016 年。褪黑激素致效劑影響晝夜節律相關標識基因之臨床表現 (CMU104-S-44)
- 國科會與波蘭國家研究發展中心交流合作計畫 2014-2016 年。憂鬱症與 n-3 不飽和脂肪酸：從細胞機轉到臨床應用－三年計劃 (NSC103-2923-B-039-002-MY3)
- 國科會與英國皇家學院交流合作計畫 2013-2015 年。Omega-3 不飽和脂肪酸在預防孕婦憂鬱症之研究－二年計劃 (102-2911-I-039-501)
- 國科會優秀年輕學者研究計畫 2012-2015 年。不飽和脂肪酸在憂鬱症之角色探討：從分子生物學、大腦影像到行為研究－三年計劃 (NSC101-2628-B-039-001-MY3)
- 中國醫藥大學 2014-2015 年。不飽和脂肪酸抗憂鬱症療效於炎症細胞模式之機轉研究 (CMU103-S-03)
- 國家衛生研究院整合性醫藥衛生科技研究計畫 (創新研究計畫) 2012-2014 年。經顱磁刺激之神經、心理及生物效應研究：以腦磁刺激療法探討憂鬱症之身心介面 (NHRI-EX101-10144NI)。
- 中國醫藥大學附設醫院 2013-2014 年。星狀膠細胞對 glutamate 造成皮質神經細胞興奮性毒性之保護作用 (DMR-103-078)
- 國科會補助國內舉辦國際學術研討會：第三屆身心介面國際研討會 (102-2916-I-039-003-A1)
- 中國醫藥大學附設醫院 2012-2013 年。C 型肝炎患者接受干擾素治療引發憂鬱症之基因標誌 (DMR-102-068)
- 中國醫藥大學附設醫院 2011-2012 年。探討憂鬱症之異質性：基因標誌在憂鬱症之重要性 (DMR-101-081)
- 國科會跨領域整合型計畫 2009-2012 年。「干擾素- α 治療引致憂鬱症之認知及生物機制：由臨床認知功能與神經細胞機轉來探討」：干擾素- α 對 C 型肝炎病患週邊血液發炎指標之影響並探討引致憂鬱症與否之效果〈總計畫及子計畫一之計畫主持人〉－三年計劃 (NSC 98(99&100)-2627-B-039-003)
- 國科會傑出學者養成型計畫 2009-2012 年。干擾素誘發憂鬱症之預防及治療：N-3 多元不飽和脂肪酸之安慰劑雙盲對照組研究－三年計劃 (NSC 98-2628-B-039-020-MY3)
- 國科會 2010「台灣與英國頂尖大學前期合作研究計畫」由多元不飽和脂肪酸探討憂鬱症之生物機轉 (NSC 99-2911-I-039-002)。
- 「美國國家精神分裂症及憂鬱症研究聯盟 (NARSAD)」2008-2010 二年計劃。憂鬱症身體化症狀之之生物標記－多元不飽和脂肪酸
- 生技製藥國家型科技計畫「轉譯醫學研究計畫」2008-2010。探討多元

不飽和脂肪酸做為憂鬱症分型之生物標記—二年計劃
(97-2-TRA-001)

- 中國醫藥大學附設醫院 2009-2010 年。週邊淋巴球上 PLA2 和 COX-2 的基因表現在干擾素- α 引致憂鬱症之重要性 (DMR99-114)
- 中國醫藥大學 2009-2010 年。神經認知及發炎生物指標在干擾素- α 治療引致憂鬱症之重要性：探索性先驅研究 (CMU97-336)
- 國科會 2006-2009 年。不飽和脂肪酸在 C 型肝炎患者接受干擾素治療誘發的身心副作用之角色探討—三年計劃 (NSC 95-2320-B-039-037-MY3)
- 中國醫藥大學 2007-2008。由蛋白質體學探討 C 型肝炎患者接受干擾素治療誘發生病行為及憂鬱症之病理機轉 (CMU95-143)
- 衛生署 2006-2007。深海魚油對雙極型情感性精神病之保健功效：由雙盲對照試驗探討 omega-3 fatty acids 對改善雙極型情感性精神病之急性鬱期及復發預防之效果—二年計劃 (DOH 95F022)
- 國科會 2005-2006 年。深海魚油對於大鼠在強迫游泳試驗之作用。(NSC 94-2314-B-039-027)
- 衛生署 2005-2007。深海魚油對憂鬱症之保健功效：由雙盲對照試驗研究來探討 omega-3 fatty acids 在憂鬱症之預防與治療—三年計劃 (DOH 94F044)
- 國科會 2002-2005 年。Omega-3 多不飽和脂肪酸在產前及產後憂鬱症之重要性：流行病學、精神病生理學、飲食頻率、及雙盲療效研究—三年計劃 (NSC 91-2320-B-039-017, 92-2320-B-039-026, 93-2320-B-039-001)
- 國科會 2001-2004 年。Omega-3 多不飽和脂肪酸在精神分裂症之重要性：雙盲療效研究、精神病生理學及飲食頻率之探討—三年計劃。(NSC90-2320-B-038-046, 91-2320-B-039-010, 92-2320-B-039-025)
- 國科會 2000-2001 年。N-3 多不飽和脂肪酸對於重度憂鬱症之臨床意義：紅血球中脂肪酸組成的監測及平行組間、雙盲對照之療效研究。(NSC89-2320-B-038-046)
- 中國醫藥大學附設醫院 2003-2004。新一代抗精神病藥物對於脂質、糖類代謝及 leptin 影響在精神分裂症患者之重要性 (DMR-92-017)
- 中國醫藥大學 2004-2005。Omega-3 多不飽和脂肪酸對於大鼠在 forced-swimming test 中「類似憂鬱行為」的作用 (CMU93-M-24)
- 中國醫藥大學 2005-2006。Omega-3 多不飽和脂肪酸對於大鼠在「reserpine 誘發類似憂鬱行為」的作用。(CMU94-105)
- 台北醫學院 1999-2000 年。N-3 多不飽和脂肪酸對於重度憂鬱症病人之治療：平行組間、雙盲對照之研究。(TMC88-Y05-A121)

共同主持人：

- 科技部 2017-2018 年。褪黑激素受體致效劑及 omega-3 脂肪酸對節律

調節及神經保護的作用：從細胞實驗、動物模型到臨床研究
(MOST106-2314-B-038-049)

- 科技部 2017-2018 年。台灣精神疾病臨床試驗合作聯盟
(MOST106-2321-B-039-004)
- 科技部 2017-2018 年。減重手術對進食行為、憂鬱、發炎及腸道微生物的影響：動物實驗與臨床醫學實證 (MOST 106-2314-B-039-031)
- 科技部 2017-2018 年。Omega-3 脂肪酸對急性冠狀動脈綜合症後之重鬱症雙盲安慰劑療效研究 (MOST106-2314-B-039-035)
- 科技部 2017-2018 年。憂鬱症患者使用不同抗憂鬱劑的醫療利用與費用以及不遵醫囑與自殺行為的風險之比較分析
(MOST106-2410-H-038-018)
- 科技部 2015-2018 年。Omega-3 多元不飽和脂肪酸對心血管疾病患者共患憂鬱症的雙盲療效研究—三年計劃 (MOST104-2314-B-039-050-MY3)
- 科技部 2015-2016 年。接受長效型 Risperidone 注射劑治療的精神分裂症患者之醫療照護利用與費用以及精神科醫師對於開立抗精神病藥物長效針劑的醫療決策之探討 (MOST104-2410-H-038-007)
- 科技部 2014-2017 年。探索和鑒別不飽和脂肪酸之間的功能關係和相互作用以及在治療抑鬱症和神經退變性疾病中的抗炎和神經保護機制—三年計劃 (MOST103-2320-B-039-041-MY3)
- 科技部 2014-2017 年。Omega-3 fatty acids 在憂鬱症治療的機制：由慢性壓力反應、神經新生和發炎的關係來探討 EPA 及 DHA 的神經效應—三年計劃 (MOST103-2320-B-038-012-MY3)
- 科技部 2014-2015 年。N-3 多元不飽和脂肪酸對注意力缺陷過動症兒童的雙盲療效研究 (MOST103-2320-B-039-030)
- Japan Society for the Promotion of Science 2013-2015 年。The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO) —三年計劃 (JSPS 25702043)
- 科技部 2014-2016 年。台灣精神疾病臨床試驗合作聯盟
(MOST103-2325-B-039-005)
- 國科會 2013-2014 年。srpk2 基因剔除小鼠之建立及其致病機轉的探討 (NSC 102-2320-B-039-039) —一年計劃
- 國科會 2012-2014 年。N-3 多元不飽和脂肪酸改善干擾素誘發憂鬱症之生物機轉 (NSC 101-2320-B-038-020-MY2) —二年計劃
- 國科會 2009-2012 年。從脂肪酸代謝酵素 PLA2 及 COX2 之基因多形性及基因表現探討 n-3 不飽和脂肪酸在憂鬱症之重要性—三年計劃
(NSC 98-2320-B-038-018-MY3)
- 國科會 2009-2012 年。抗憂鬱劑治療對身體健康之重鬱症患者的白血球與血小板交互作用之研究—三年計劃 (NSC 98-2314-B-039-011-MY3)

- 衛生署中醫藥委員會 2006-2007。天麻水萃物在動物實驗及臨床試驗中的抗憂鬱效果及其機制之探討。(CCMP95-RD-033)
- 國科會 2006-2007。從台灣全民健康保險門診與住院資料探討糖尿病患者同時覆合罹患憂鬱症的影響。(NSC 95)
- 國科會 2005-2007。以功能性磁共振造影評估憂鬱症病患經不同作用機轉之藥物治療前後其中樞神經精神生物機轉路徑之差異性—二年計劃。(NSC 94-2314-B-039-011, NSC 95-2314-B-039-003)
- 國科會 2004-2005。Omega-3 多不飽和脂肪酸輔助 clozapine 對精神分裂症之療效及對單胺類代謝之影響。(93-2314-B-109-007)
- 國科會 2003-2004。探討精神分裂症的指紋及不對稱指標之研究。(NSC 92-2320-B-039-020)
- 衛生署 2003-2005。從飲食攝取、脂肪酸代謝探討 Omega-3 不飽和脂肪酸和阿茲海默症之關聯性及其延緩智能退化效果之評估—二年計劃 (DOH92-TD-1095)
- 國科會 2002-2003。新一代抗精神藥物所引發體重增加及血脂異常:機制之探討與 omega-3 多不飽和脂肪酸的療效。(NSC91-2314-B109-003)
- 國科會 2001-2002。從飲食攝取、脂肪酸代謝及酵素關點探討憂鬱症與 n-3 多元不飽和脂肪酸之相關性：台灣地區常模之建立。(NSC 90-2320-B-038-057)
- 台灣版「愛丁堡產後憂鬱症量表」在產前及產後憂鬱症篩檢之信、效度研究 (DMR-92-92)
- 懷孕期及產後憂鬱症之盛行率及其危險預測因子之研究(DMR-94-46)

期刊或研究計劃
審查者

國內外研究計劃審查 (至今共五十餘件): 詳見附件

國際期刊審查 (至今共八十餘篇): 詳見附件

著作論文報告

見下頁

研究成果目錄：論文及著述

(1) Referred Paper

1. Lin PY, Chang CH, Chongc MFF, Chen H, Su KP*. Polyunsaturated fatty acids in perinatal depression: A systematic review and meta-analysis. **Biological Psychiatry** (Accepted) doi: 10.1016/j.biopsych.2017.02.1182. [Epub ahead of print]
2. Chang JPC, Su KP, Mondelli V, Pariante C. Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review and Meta-analysis of Clinical Trials and Biological Studies. **Neuropsychopharmacology** (Accepted) doi: 10.1038/npp.2017.160. [Epub ahead of print]
3. Borsini A, Alboni S, Horowitz MA, Tojoa LM, Cannazza G, Su KP, Pariante CM, Zunszain PA. Rescue of IL-1 β -induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants. **Brain, Behavior, and Immunity** (Accepted).
4. Gałecka E, Talarowska M, Maes M, Su KP, Górski P, Kumor-Kisiełowska A, Szemraj J. Expression levels of interferon- γ and type 2 deiodinase in patients diagnosed with recurrent depressive disorders **Pharmacological Reports** (Accepted).
5. Su KP*, Yang HT, Chang JP, Shih YH, Guu TW, Kumaran SS, Gałecki P, Walczewska A, Pariante CM. Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** (Accepted) doi: 10.1016/j.pnpbp.2017.06.020 [Epub ahead of print].
6. Chang JPC, Lin CY, Lin PY, Shih YH, Chiu TH, Ho M, Yang HT, Huang SY, Gałecki P, Su KP*. Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** (Accepted) doi: 10.1016/j.pnpbp.2017.05.008. [Epub ahead of print] (Accepted).
7. Zgórzyńska E, Dziejcz B, Gorzkiewicz A, Stulczewski D, Bielawska K, Su KP, Walczewska A. Omega-3 polyunsaturated fatty acids improve the antioxidative defense in rat astrocytes via an Nrf2-dependent mechanism. **Pharmacological Reports** (Accepted) doi: 10.1016/j.pharep.2017.04.009. [Epub ahead of print].
8. Chang JPC, Guu TW, Chen YC, Gałecki P, Walczewska A, Su KP. BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients. **Prostaglandins Leukotrienes and Essential Fatty Acids** (In Press) doi: 10.1016/j.plefa.2017.01.001. [Epub ahead of print]
9. Yang HT, Wang RY, Huang SY, Huang CL, Su KP. Genetic polymorphisms of FADS1, FADS2, and FADS3 and fatty acid profiles in subjects received methadone maintenance therapy. **Prostaglandins Leukotrienes and Essential Fatty Acids** (In Press) doi: 10.1016/j.plefa.2017.01.006. [Epub ahead of print]
10. Chang JPC, Lai HC, Yang HT, Su WP, Peng CY, Gałecki P, Walczewska A, Pariante CM, Su KP*. Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. **Nutritional Neuroscience** 2017; 20 (5), 291-296.
11. Lee CWS, Lin CL, Lin PY, Thieke S, Su KP, Kao CH. Antidepressants and risk of dementia in

migraine patients: A population-based case-control study. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2017; 77: 83-89.

12. Chiu WC, Su YP, Su KP, Chen PC. Recurrence of Depressive Disorders after Interferon-induced Depression. **Translational Psychiatry** 2017 Feb; 7(2): e1026.
13. Chang JPC, Li JL, Huang YT, Lu YJ, Su KP*. Delay Aversion, Temporal Processing and N-3 Fatty Acids Intake in Children with Attention Deficit Hyperactivity Disorder (ADHD). **Clinical Psychological Science** 2016; 4(6): 1094-1103.
14. Chen YT, Su KP, Chang JP. Atypical major depressive episode as initial presentation of intracranial germinoma in a male adolescent. **Neuropsychiatric Disease and Treatment** 2016 Dec;13:35-40.
15. Nishi D, Su KP*, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Tachibana Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka Y. The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial. **BMC Psychiatry** 2016 Sep; 16:321 (DOI: 10.1186/s12888-016-1031-2).
16. Hsiao PJ, Hsieh PF, Chou EC, Lai HC, Peng CY, Su KP. Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C. **PLoS One** 2016 Aug 9; 11(8): e0160450.
17. Nishi D, Su KP*, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka YJ. Omega-3 fatty acid supplementation for expectant mothers with depressive symptoms in Japan and Taiwan: An open-label trial. **Psychiatry and Clinical Neuroscience** 2016 Jun; 70(6): 253-4.
18. Senthil Kumaran S, Shih YH, Su KP*. Detecting the modest signals of omega-3 fatty acids' antidepressant effects by homogenizing depressed patient groups. **Lipid Technology** 2016 May/June; 28: 86-87.
19. Gałecka E, Talarowska M, Maes M, Su KP, Górski P, Szemraj J. Polymorphisms of iodothyronine deiodinases (DIO1, DIO3) genes are not associated with recurrent depressive disorder. **Pharmacological Reports** 2016 May; 68(5): 913-917.
20. Chang HC, Huang KC, Chiu WC, Huang KC, Tang CH, Su KP*. Changes in employment status in bipolar disorder: a longitudinal study with national claims data. **Journal of Clinical Psychiatry** 2016 Apr; 77(4): e429-35.
21. Kwiatkowski D, Czarny P, Toma M, Jurkowska N, Sliwiska A, Drzewoski J, Bachurska A, Bielecka-Kowalska A, Szemraj J, Maes M, Berk M, Su KP, Galecki P, Śliwiński T. Associations between DNA damage, DNA base excision repair genes variability and Alzheimer's disease risk. **Dementia and Geriatric Cognitive Disorders** 2016; 41(3-4): 152-71.
22. Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: acting separately or synergistically? **Progress in Lipid Research** 2016 Jan; 62: 41-54.
23. Su KP*. Personalize medicine with omega-3 fatty acids for depression in pregnant women and children, and depression associated with inflammation. **Journal of Clinical Psychiatry** 2015; 76 (11): e1476-7.
24. Su KP*. Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon- α -induced depression. **BioMedicine** 2015; 5(4): 17-23

25. Sarris J, Nishi D, Xiang YT, Su KP, Bannatyne A, Oliver G, Heok KE, Ng C. Implementation of Psychiatric-Focused Lifestyle Medicine Programs in Asia. **Asia-Pacific Psychiatry** 2015 Dec; 7(4): 345-54.
26. Sarris J, Logan A, Akbaraly T, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. **World Psychiatry** 2015 Oct; 14(3): 370-1.
27. Song C, Luchtman D, Kang Z, Tam EM, Yatham LN, Su KP, Lam RW. Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. **Journal of Affective Disorders** 2015 Oct 1; 185: 90-6.
28. Su KP*, Matsuoka Y, Pae CU. Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. **Clinical Psychopharmacology and Neuroscience** 2015 Aug 31; 13(2):129-37.
29. Czarny P, Kwiatkowski D, Gałecki P, Talarowska M, Orzechowska A, Bobinska K, Bielecka-Kowalska A, Szemraj J, Maes M, Su KP, Sliwinski T. Association between single nucleotide polymorphisms of MUTYH, hOGG1 and NEIL1 genes, and depression. **Journal of Affective Disorders** 2015 June 3; 184: 90-96.
30. Sarris J, Logan A, Akbaraly T, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. Nutritional Medicine as Mainstream in Psychiatry. **Lancet Psychiatry** 2015 Mar; 2(3): 271-4.
31. Chang JPC, Chang SS, Yang HT, Palani M, Chen CP, Su KP*. Polyunsaturated fatty acids levels in patients with cardiovascular diseases with and without depression. **Brain, Behavior, and Immunity** 2015 Feb; 44: 28-31.
32. Chen WC, Lai HC, Su WP, Palani M, Su KP*. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: An open-label study. **Psychiatry Investigation** 2015 Jan; 12(1):142-5.
33. Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JPC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression Results from a randomized, controlled trial. **Biological Psychiatry** 2014 Oct 1; 76(7): 559-66.
34. Talarowska M, Orzechowska A, Szemraj J, Su KP, Maes M, Gałecki P. Manganese superoxide dismutase gene expression and cognitive functions in recurrent depressive disorders. **Neuropsychobiology** 2014 Aug; 70: 23–28.
35. Chang JPC, Lin CC, Hwu HG, Su KP*. View on DSM from Taiwan: Transition from IV to 5. **Acta Psychiatrica Scandinavica** 2014 Mar; 129(3): 235.
36. Talarowska M, Bobińska K, Zajączkowska M, Su KP, Maes M, Gałecki P. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. **Medical Science Monitor** 2014 Jan; 20: 110-5.
37. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. **Expert Opinion On Investigational Drugs** 2013 Dec; 22(12): 1519-1534.
38. Lu DY, Leung YM, Su KP*. Interferon- α induces nitric oxide synthase expression and heme

oxygenase-1 down-regulation in microglia: Implications of cellular mechanism of IFN- α -induced depression. **International Journal of Neuropsychopharmacology** 2013 Mar; 16(2): 433-44.

39. Tseng YL, Chiang ML, Lane HY, Su KP, Lai YC. Selective serotonin reuptake inhibitors reduce P2Y₁₂ receptor-mediated amplification of platelet aggregation. **Thrombosis Research** 2013 Apr; 131(4): 325-32.
40. Lin SH, Chang HC, Chen PJ, Hsieh CL, Su KP, Sheen LY. The antidepressant-like effect of ethanol extract of daylily flowers in rats. **Journal of Traditional and Complementary Medicine** 2013 Jan; 3(1): 53-61.
41. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH, Su KP*. Are omega-3 fatty acids anti-depressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. **Molecular Psychiatry** 2012 Dec; 17(12): 1161-3.
42. Lin PY, Chiu CC, Huang SY, Su KP*. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. **Journal of Clinical Psychiatry** 2012; 73(9): 1245-1254.
43. Su KP. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications. **BioMedicine** 2012 June; 2(2): 68-74.
44. Chang HC, Tang CH, Huang ST, McCrone P, Su KP*. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror image study with national claim-based database in Taiwan. **Journal of Psychiatric Research** 2012 Jun; 46(6): 751-6.
45. Liang JA, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Kao CH. A nationwide population-based cohort study: Anxiety disorders will increase subsequent cancer risk? **PLoS ONE** 2012 April; 7(4): e36370, 1-6.
46. Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Liang JA. Use of benzodiazepine increases cancer risk – A population-based cohort study in Taiwan. **Journal of Clinical Psychiatry** 2012 April; 73(4): 555-560.
47. Jadoona A, Chiu CC, McDermott L, Cunningham P, Frangou S, Chang CJ, Sun YW, Liu SI, Lu ML, Su KP, Huang SY, Stewart R. Associations of polyunsaturated fatty acids with residual depression or anxiety in older people with major depression. **Journal of Affective Disorders** 2012 Feb;136(3): 918-25.
48. Chen YT, Su KP, Chang J. Early detection and management of atypical Neuroleptic malignant syndrome secondary to aripiprazole. **Schizophrenia Research** 2011 Sep; 132(1): 97-98.
49. Chen PJ, Liang KC, Lin HC, Hsieh CL, Su KP, Hung MC, Sheen LY. Gastrodia elata Bl. Attenuated Learning Deficits Induced by Forced-Swimming Stress in the Inhibitory Avoidance Task and Morris Water Maze. **J Med Food** 2011 Jun; 14(6): 610-7.
50. Guu TW, Su KP*. Musical creativity and mood bipolarity in Robert Schumann- A tribute to the 200th anniversary of the composer's birth. **Psychiatry and Clinical Neuroscience** 2011; 65: 112-114. (*Correspondence).
51. Chang J, Wu CC, Su KP*. A case of venlafaxine-induced bruxism alleviated by duloxetine substitution. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2011; 35: 307. (*Correspondence).
52. Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC. A selective serotonin reuptake inhibitor,

citalopram, inhibits collagen-induced platelet aggregation and activation. **Thrombosis Research** 2010 Dec; 126(6): 517-523.

53. Lu DY, Tsao YY, Leung YM, Su KP*. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: Implications of antidepressant effects for omega-3 fatty acids. **Neuropsychopharmacology** 2010 Oct; 35(11): 2238–2248. (*Correspondence).
54. Wu CC, Chang J, Liou JS, Su KP*. A case of milnacipran-induced sweating alleviated by duloxetine substitution. **Journal of Clinical Psychopharmacology** 2010 Oct; 30(5): 640-1. (*Correspondence).
55. Chang J, Su KP*. The lipid raft hypothesis: the relation among omega-3 fatty acids, depression and cardiovascular diseases. **Taiwanese Journal of Psychiatry** 2010 Sep; 24(3): 168-80. (*Correspondence).
56. Lin PY, Huang SY, Su KP*. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. **Biological Psychiatry** 2010; 68(2):140-147. (*Correspondence).
57. Wu CC, Tsai CH, Lu MK, Chen CM, Shen WC, Su KP*. Theta-burst repetitive transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder with concomitant depression. **Journal of Clinical Psychiatry** 2010 April; 71(4): 504-506. (*Correspondence).
58. Su KP, Huang SY, Peng CY, Lai CH, Huang CL, Chen YC, Aitchison KJ, Pariante CM. Phospholipase A2 and cyclo-oxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. **Biological Psychiatry** 2010; 67(6): 550-557.
59. Chang J, Wu CC, Su KP*. Paliperidone overdose in a patient with schizophrenia. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2010 Mar; 34(2): 418. (*Correspondence).
60. Su KP*, Chang HC*, Tsai SJ, Tang CH. Relapse and long-acting injectable risperidone: A one-year mirror image study with a national claims database in Taiwan. **Value in Health** 2009; 12(S3): S118-S121.
61. Su KP. The biological mechanism of antidepressant effect of omega-3 fatty acids: How does fish oil acts as a “mind-body interface?” **NeuroSignals** 2009 Feb; 17(2): 144-152.
62. Chang HC, Tang CH, Tsai SJ, Yen FC, Liu JP, Su KP*. Long-acting injectable risperidone and hospital readmission: A mirror image study with a national claim-based database in Taiwan. **Journal of Clinical Psychiatry** 2009 Jan; 70(1): 141. (*Correspondence).
63. Chen PJ, Hsieh CL, Su KP, Hou YC, Chiang HM, Sheen LY. Rhizomes of *Gastrodia elata* B(L) Possess Antidepressant-Like Effect via Monoamine Modulation in Subchronic Animal Model. **Am J Chin Med** 2009; 37(6): 1113-24.
64. Chang J, Wu PL, Lane HY, Su KP*. Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment for Isaacs Syndrome with Depression. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2009 Jun 15; 33(4): 739-40. (*Correspondence).
65. Chang J, Chen YT, Su KP*. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular diseases (CVD) and depression: the missing link? **Cardiovascular Psychiatry and Neurology** 2009(2009), Article ID 725310, 6 pages. doi:10.1155/2009/725310. (*Correspondence).
66. Wu CC, Su KP. Quetiapine-induced Rabbit Syndrome in a patient with bipolar disorder. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008 Dec; 32(8):2002-3.

67. Chiu CC, Liu JP, Su KP*. The use of omega-3 fatty acids in treatment of depression: the lights and shadows. **Psychiatric Times** 2008 Aug; 25(9): 76-80. (*Correspondence).
68. Su KP*, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. **Journal of Clinical Psychiatry** 2008 Apr; 69(4): 644-651. (*Correspondence).
69. Chiu CC, Su KP, Cheng TC, Liu HC, Stewart R, Huang SY. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008; 32(6): 1538–1544.
70. Liao CC, Huang CL, Chang YH, Lin CC, Su KP*. Red Yeast Rice for a patient with olanzapine-induced dyslipidemia: a test-and-retest case report. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008 Jul; 32(5): 1340-1341. (*Correspondence).
71. Wang JF, Lin CL, Chang YH, Chen TY, Su KP, Nagurka ML. Determining the association between dermatoglyphics and schizophrenia by using fingerprint asymmetry measures. **International Journal of Pattern Recognition and Artificial Intelligence** 2008; 22(3): 601-616.
72. Chen PJ, Hsieh CL, Su KP, Hou YC, Chiang HM, Lin IH, Sheen LY. The Antidepressant Effect of *Gastrodia elata* Bl. on the Forced-Swimming Test in Rats. **American Journal of Chinese Medicine** 2008 Jan; 36(1): 95-106.
73. Su KP*. Mind-body interface: The role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression. **Asia Pacific Journal of Clinical Nutrition** 2008 Jan; 17(S1): 147-153.
74. Huang SY, Yang HT, Chiu CC, Pariante C, Su KP*. Omega-3 fatty acids on the forced-swimming test. **Journal of Psychiatric Research** 2008 Jan; 42(1): 58-63. (*Correspondence).
75. Su KP*, Chiu TH, Huang CL, Ho M, Lee CC, Wu PL, Lin CY, Liao CH, Liao CC, Chiu WC, Pariante CM. Different cut-off points for different trimesters? The use of Edinburgh Postnatal Depression Scale and Beck Depression Inventory to screen depression during pregnancy in Taiwan. **General Hospital Psychiatry** 2007 Sep-Oct; 29(5): 436-41. (*Correspondence).
76. Lin PY, Su KP*. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. **Journal of Clinical Psychiatry** 2007 Jul; 68(7): 1056–1061. (*Correspondence).
77. Wu PL, Liao KF, Peng CY, Pariante CM, Su KP*. Manic episode associated with citalopram therapy for IFN-induced depression in a patient with chronic hepatitis C infection. **General Hospital Psychiatry** 2007 Jul-Aug; 29(4): 374-6. (*Correspondence).
78. Huang CL, Su KP*, Hsu HB, Pariante C. A pilot crossover study on QTc interval associated with olanzapine and risperidone. **Journal of Clinical Psychiatry** 2007 May; 68(5): 803-5. (*Correspondence).
79. Lin CY, Wu PL, Pariante C, Su KP*. A crossover study on prolactin changes associated with risperidone and olanzapine. **Journal of Clinical Psychiatry** 2006 Sep; 67(9): 1470-1471. (*Correspondence).

80. Liau CH, Shen WW, Su KP*. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient. **Psychiatry and Clinical Neuroscience** 2006; 60(1): 121-122. (*Correspondence).
81. Wu PL, Lane HY, Su KP*. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus. **Psychiatry and Clinical Neuroscience** 2006; 60(1): 115-116. (*Correspondence).
82. Chiu CC, Huang SY, Chen CC, Su KP*. Omega-3 fatty acids is more beneficial to depression than to mania in patients with bipolar I disorder. **Journal of Clinical Psychiatry** 2005 Dec; 66(12): 1613-14. (*Correspondence).
83. Su KP*, Wu PL, Pariante C. A crossover study on of lipid and weight changes associated with olanzapine and risperidone. **Psychopharmacology** 2005 Dec; 183(3):383-386. (*Correspondence).
84. Huang SY, Chiu CC, Shen WW, Chang HC, Su KP*. Hypoalbuminemia in drug-free patients with major depressive disorder compared with a dietary matched control group: A clinical meaning beyond malnutrition. **European Neuropsychopharmacology** 2005; 15(2): 227-230. (*Correspondence).
85. Chiu CC, Huang SY, Su KP*. Omega-3 polyunsaturated fatty acids for postpartum depression. **American Journal of Obstetrics and Gynecology** 2004; 190 (2): 582-583. (*Correspondence).
86. Su KP, Chuang CL, Chen KP, Lane HY, Shen WW. Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. **Schizophrenia Research** 2004; 66 (2-3): 191-192.
87. Huang SY*, Wu SS, Chiu CC, Kuo CJ, Su KP, Lu ML. Assessment of Dietary Intake and Blood Fatty Acid Composition in Patients with Schizophrenia. **Nutrition Science Journal** 2004; 29(1): 21-30. [Full text in Chinese]
88. Su KP*, Huang SY*, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. **European Neuropsychopharmacology** 2003; 13(4): 267-271. (*Correspondence).
89. Chiu CC, Huang SY, Su KP*, Lu ML, Huang MC, Chen CC, Shen WW. Polyunsaturated fatty acid deficit in patients with bipolar mania. **European Neuropsychopharmacology** 2003; 13(2): 99-103. (*Correspondence).
90. Chiu CC, Huang SY, Shen WW, Su KP*. Omega-3 fatty acid monotherapy for a pregnant patient with major depressive disorder. **American Journal of Psychiatry** 2003; 160(2): 385. (*Correspondence) **[Erratum on affiliation: American Journal of Psychiatry 2003; 160 (4): 801]**
91. Su KP, Chuang CL, Chen KP, Chen CC, Shen WW. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol use. **Schizophrenia Research** 2003; 59(1): 93-34.
92. Su KP, Leu SYC, Yang YY, Shen WW, Chou YM, Tsai SYM. The change of interferon-gamma and interleukine-10 in bipolar mania and subsequent remission. **Journal of Affective Disorders** 2002; 71: 205-9. **[Erratum on affiliation: Journal of Affective Disorders 2003; 73: 299]**
93. Lu ML, Pan JJ, Teng HW, Su KP, Shen WW. Metoclopramide-Induced supersensitivity psychosis. **Annals of Pharmacotherapy** 2002; 36: 1387-90.
94. Su KP, Chang HC, Shen WW. QTc Prolongation associated with haloperidol, risperidone and ziprasidone. **American Journal of Psychiatry** 2002; 159: 1062-1063.

95. Pan CC, Shen WW, Su KP*. Individual psychotherapy for transsexualism with the co-morbidity of depressive disorder - 3 cases reports. **Taiwanese Journal of Psychiatry** 2002; 16(3): 237-242. (*Correspondence)
 96. Su KP, Huang SY, Shen WW. Brief review on lipid abnormalities induced by novel antipsychotic drugs. **Drug Safety** 2001; 24 (13): 1017-8.
 97. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. **European Neuropsychopharmacology** 2001; 11(4): 295-299.
 98. Su KP, Hsu CY, Hsieh SC, Shen WW. Magnetic resonance imaging findings in patients with delusional disorder due to diffuse cerebrovascular disease: a report of seven cases. **Psychiatry and Clinical Neuroscience** 2001; 55(2): 121-126
 99. Hsieh WC, Shen WW, Pan CC, Su KP*. Intensive stress-management Group psychotherapy on outpatients with anxiety disorders: a pilot demonstration. **Taiwanese Journal of Psychiatry** 2001; 15(2): 117-125. (*Correspondence).
 100. Su KP, Yu JM, Yang TW, Tsai SY, Chen CC. Mentally retarded criminal offenders in northern Taiwan. **Journal of Forensic Science** 2000; 45(6): 1207-1209
 101. Su KP, Huang SY, Shen WW. Effects of polyunsaturated fatty acids on psychiatric disorders. **American Journal of Clinical Nutrition** 2000; 72(5): 1241
 102. Shen WW, Su KP. Torsadogenicity and antipsychotic drugs. **Taiwanese Journal of Psychiatry** 2000; 14(3): 6-22.
 103. Su KP, Huang SY, Shen WW. Is omega 3 fatty acids beneficial in depression but not mania? **Archives of General Psychiatry** 2000; 57(7): 716.
 104. Su KP, Tsai SY, Huang SY. Cholesterol, depression and suicide. **British Journal of Psychiatry** 2000; 176(4): 399.
 105. Su KP, Lee HC, Pan CC, Tsai SY. The screening of depressed mood in the elderly Taiwanese. **New Taipei Journal of Medicine** 2000; 2(2): 81.
 106. Su KP, Lee HC, Pan CC, Huang SY. Lipid and psychiatric disorders: Does total serum cholesterol matter? **Taiwanese Journal of Psychiatry** 2000; 14(1): 77-9.
 107. Su KP, Lee YJ, Lee MB. Severe peripheral polyneuropathy and rhabdomyolysis in lithium intoxication: a case report. **General Hospital Psychiatry** 1999; 21(2): 136-7.
 108. Lane HY, Su KP, Chang WH. Seizures after Discontinuation of Low-Dose Lorazepam From Originally Seizure-Free Clozapine Regimen: Combined Effects? **Journal of Clinical Psychiatry** 1999; 60(6): 408-409.
 109. Lane HY, Su KP, Chang WH. Elevated plasma clozapine concentrations after phenobarbital discontinuation. **Journal of Clinical Psychiatry** 1998; 59(3): 131-3.
- **SSCI/SCI: 99 (first author: 27, *Correspondence author: 46)**
 - **Impact Factors>10: 10 papers**
 - **Impact Factors>5: 33 papers**

(2) Book chapter

1. Su KP, Balanzá-Martínez V. Role of omega-3 fatty acids in mood disorders (Chapter 16). In McNamara RK, Editor. *The omega-3 fatty acid deficiency syndrome: opportunities for disease prevention*. Nova Science Pub Inc., NY, USA: 2013, pp. 315-336 (ISBN 978-1-62417-703-3).
2. Chang JPC, Su KP. Omega-3 polyunsaturated fatty acids (PUFAs) as the “Mind-Body Interface” in cardiovascular diseases and depression. In: Rodriguez-Cruz M, Editor. *The latest finding of the long chain polyunsaturated fatty acids: since molecular mechanism to new application in the health*. Bentham Science Publishers, Bussum, Netherlands: 2011, pp. 58-66. (ISBN 978-1-60805-356-8)
3. Su KP, Shen WW, Huang SY. The use of omega-3 fatty acids for the management of depression and psychosis during pregnancy and breast-feeding. In: Peet M, Glen I, Horrobin DF, Editors. *Phospholipid spectrum disorder in psychiatry and neurology*, 2nd ed. Marius Press, 2003, Carnforth, UK: pp. 391-399. (ISBN 978-1871622256)

(3) 研討會論文 (Conference Papers in 5 years)

1. Su KP. Omega-3 fatty acids support brain, mind and body: From bench to bedside, The 26th Japanese Society of Lipid Nutrition (JSLN), Tokyo, Japan, Sep 22-23, 2017 (**Keynote Speaker**)
2. Su KP. (1) The devil is in the details: Insights from clinical studies of omega-3 fatty acids in depression (**Keynote**); (2) Personalized medicine with omega-3 fatty acids in treatment of depression associated with inflammation (Symposium: Omega-3 polyunsaturated fatty acid in prevention of depression and post-traumatic stress in person with special physical condition, **Speaker**); (3) Polyunsaturated fatty acids in perinatal depression: A systematic review and meta-analysis (Symposium: Promoting Nutritional Psychiatry Research from Taiwan, **Speaker and Chair**), The 2017 Annual Congress International Society for Nutritional Psychiatry Research (ISNPR), Marriott Hotel Bethesda, Washington DC, USA, July 30-Aug 2, 2017 (**Symposium Chair and Keynote Speaker**)
3. Su KP. Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application (S-08: Inflammation markers of peripheral blood in depression spectrum), The 13th World Congress of Biological Psychiatry, in Copenhagen, Denmark, June 18-22, 2017 (**Symposium Speaker**)
4. Su KP. Omega-3 fatty acids for depression. The 4th International Forum on Omega-3 and Human Health, Chongqing, China, March 2-3, 2017 (**Keynote speaker**)
5. Su KP. Omega-3 and Health Promotion & Disease Management: From Animals to Humans. Inaugural symposium of the International Society for Omega-3 Research: Boston, USA, Jan 8-9, 2017 (**Keynote speaker**)
6. Su KP. (1) “The devil is in the details: insights from clinical studies of nutritional intervention in depression” in the symposium of “Nutritional medicine as mainstream in psychiatry” and (2) “Personalized medicine with fish oils for depression” in the symposium of “Lifestyle medicine and nutraceuticals in psychiatry” @ The 17th Pacific Rim College of Psychiatrists (PRCP) Congress, Kaohsiung, Taiwan, Nov 3-5, 2016 (**Symposium Chair and Speaker**)
7. Su KP. Personalized medicine with omega-3 fatty acids for depression. The 9th International Stress and Behavior Society (ISBS) Conference, Guangdong Ocean University, Zhanjiang, China, Oct 27-29, 2016 (**Keynote speaker**)
8. Su KP. The devil is in the details: insights from clinical studies of omega-3 fatty acids in depression. ISSFAL EARLY CAREER AWARD LECTURE on 2016/9/9; Chairman of the Concurrent 23, Fatty Acids and Lipids in

- Aging on 2016/9/9; The 12th Biennial International Society for the Study of Fatty Acids and Lipids (ISSFAL), Stellenbosch, South Africa, September 5-9, 2016 (**Keynote speaker**)
9. Su KP. Clinical and biological aspects of personalizing omega-3 fatty acids in depression. The ISNPR International Satellite Symposium @ the 18th Annual Conference of the International Society for Bipolar Disorders (ISBD) and the 8th Biennial Conference of The International Society for Affective Disorders (ISAD), Amsterdam, Netherland, July 13-16, 2016 (**Symposium Speaker**)
 10. Su KP. Personalize medicine with omega-3 fatty acids for depression. The Annual Congress of Polish Psychiatric Association, Katowice, Poland, June 16-18, 2016 (**Invited Speaker**)
 11. Su KP. Personalize medicine with omega-3 fatty acids for depression, Annual International Symposium at the Chonnam National University Medical School, Gwangju, Korea, May 27-29, 2016 (**Invited Speaker**)
 12. Su KP. Omega-3 fatty acids for inflammation-related depression, in the Symposium "Biological mechanisms underlying Inflammation in psychiatric disorders: classification and therapeutic applications" in the 71st Annual Congress of SOBP, on May 12-14, 2016 in Atlanta, Georgia, USA (**Symposium Speaker**)
 13. Su KP. The World Psychiatry Association International Congress (WPAIC), Taipei, Taiwan, November 18-22, 2015 (**Congress Committee, Symposium Chair and Invited Speaker**)
 - (1) 2015/11/20 (Fri), 0830-1000, **Moderator** in the YIA Psychosomatics session;
 - (2) 2015/11/20 (Fri) 1500-1530, **Special Lecture 4**, Personalize Medicine with Omega-3 Fatty Acids for Depression, WPAIC Special Lecture;
 - (3) 2015/11/21 (Sat) 1600-1730, **Invited Speaker**, Experimental Frontiers in Treatment for Depression, WPAIC AsCNP Symposium
 14. Su KP. Personalize medicine with omega-3 fatty acids for depression, @ the International Conference on Nutrition and Physical Activity (NAPA): Healthy Lifestyle to Improve Quality of Life, Prof Sheen, Taipei, Taiwan, October 21-24, 2015 (**Conference Vice President, Symposium Chair and Speaker**)
 15. Su KP. (1) Opening remarks; (2) Moderator for Tom Brenna; (3) Moderator for Felice Jacka, The 5th MBI International Symposium, Taichung, Taiwan, October 20-21, 2015 (**Symposium Committee Chair and Speaker**)
 16. Su KP. Personalize medicine with omega-3 fatty acids for depression, Organized by Dr Mizoue for the 62nd Annual Meeting of the Japanese Society of Nutrition and Dietetics, Fukuoka, Japan, September 24-26, 2015 (**Keynote speaker**)
 17. Su KP*. "Omega-3 PUFAs in major depressive disorder in pregnant women" from the symposium titled "Challenge of nutritional psychiatry to depression in pregnant women", The 23rd World Congress of Psychosomatic Medicine (WCPM: <http://www.icpm2015.com>), Glasgow, UK August 19-22, 2015 (Invited Speaker)
 18. Su KP*. Mind-Body Interface: From Bedside to Bench for Omega-3 Fatty Acids in Depression, Polish Institute of Neurobiology (Nencki Institute of Polish Academy of Sciences), Warsaw, Poland, July 28, 2015 (**Invited Speaker**)
 19. Su KP*. Personalize medicine with omega-3 fatty acids for depression, The 70th Annual Scientific Convention of Society of Biological Psychiatry, Toronto, Ontario, Canada, May 14-16, 2015 (**Symposium Chair and Speaker**)
 20. Su KP*. How Omega-3 Fatty Acids Interface Mind and Body, The XVI World Congress of Psychiatry, Madrid, Spain, 14th – 18th September, 2014 (Invited Speaker)
 21. Su KP*. N3 in prevention of IFN-induced depression, The 11th Biennial International Society for the Study of Fatty Acids and Lipids (ISSFAL), Stockholm, Sweden, 28th June – 2nd July, 2014 (**New Investigator Award**, oral presentation)
 22. Su KP*. Omega-3 fatty acids in treatment and prevention of major depression, The 2nd ISNPR Meeting, Deakin City Centre, Melbourne, Australia, 3rd-4th, April, 2014 (Invited keynote speaker)

23. Su KP*. Health service utilization and long-acting injectable antipsychotic treatment: results from the national claim-based database in Taiwan. Symposium of Phase Specific Treatment of Schizophrenia with Christoph, Taishiro & Kane. The 3rd Asian College of Neuropsychopharmacology (AsCNP), Beijing, China, 11th-14th, September, 2013 (Invited Speaker)
24. Su KP*. Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications. The Annual Meeting of British Association for Psychopharmacology (BAP), Harrogate, UK, 28 - 21 July, 2013. (**BAP Psychopharmacology Award**, Invited Speaker)
25. Su KP*. Mind-Body Interface: Omega-3 fatty acids in the prevention of interferon-alpha-induced depression, The 11th World Congress of Biological Psychiatry, in Kyoto, Japan, 23 - 27 June 2013 (Invited Speaker)
26. Su KP* & Yutaka Matsuoka. Overview of Nutritional Psychiatry. The 1st International Society of Nutritional Psychiatry Research (ISNPR), at the National Institute of Health and Nutrition in Tokyo, Japan, 21st June, 2013 (Symposium Chairs)
27. Su KP*. Omega-3 in depression: the biological, therapeutic and preventive implications, The 1st International Society of Nutritional Psychiatry Research (ISNPR), at the National Institute of Health and Nutrition, Tokyo, Japan, 21st June, 2013 (Invited Speaker)
28. Su KP*. Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications. The Global Omega-3 Summit 2013, Crowne Plaza Le Palace, Brussels, Belgium, 30th May, 2013 (Invited keynote speaker).
29. Su KP*. Omega-3 fatty acids in the prevention of interferon-induced depression. The CINP Thematic Meeting on Personalised Medicine, Jerusalem, Israel, 21-23, April, 2013 (Invited Speaker)

(4) 其他專業著作 (<https://cobolsu.blogspot.tw>)